S 1040
Drug Competition Enhancement Act
Jurisdiction
US Congress
Session
119th Congress (2025-2026)
Last updated at
Jun 14, 2026, 8:40 AM
Take action
Sign in to record your position, submit testimony, or contact your legislator.
Sign in to take action- Introduced
- Passed Senate
- Passed House
- To President
- Became Law
Bill overview
The Drug Competition Enhancement Act aims to prevent pharmaceutical companies from engaging in ‘product hopping,’ a practice where they quickly switch to a slightly modified version of a drug after the patent on the original drug expires, with the goal of limiting competition from generic or biosimilar drugs. The bill establishes a legal presumption that product hopping has occurred under certain circumstances and grants the Federal Trade Commission (FTC) the authority to investigate and take action against manufacturers who engage in this practice. It seeks to ensure that generic and biosimilar drugs can compete effectively and provide affordable medication options for patients.
Sponsors
Official sponsors from legislative records.
Primary sponsor
Cosponsors
Arguments in favor
Reasons to support this legislation.
No arguments in favor have been submitted.
Submit yoursArguments opposed
Reasons to oppose this legislation.
No arguments opposed have been submitted.
Submit yoursRead the latest version inline or switch to a previous version.